Market Overview

JP Morgan Upgrades Pacific Biosciences to Overweight, Announces $15 Price Target

Share:

This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

Latest Ratings for PACB

DateFirmActionFromTo
Oct 2020JP MorganUpgradesNeutralOverweight
Oct 2020Piper SandlerMaintainsOverweight
Sep 2020Morgan StanleyInitiates Coverage OnEqual-Weight

View More Analyst Ratings for PACB
View the Latest Analyst Ratings

 

Related Articles (PACB)

Posted-In: News Upgrades Price Target Analyst Ratings

Latest Ratings

StockFirmActionPT
EFNCredit SuisseInitiates Coverage On19.0
KOMorgan StanleyMaintains57.0
SRCredit SuisseUpgrades68.0
CHKPMorgan StanleyMaintains109.0
COFMorgan StanleyMaintains77.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com